News
November 29, 2025
MRO’s Bold Bet on AI Sparks New Race to Speed Up U.S. Clinical Trials
NORRISTOWN, PA — MRO has acquired Clinetic, a fast-growing recruitment management platform that uses artificial intelligence to help hospitals and life sciences companies identify, screen and enroll clinical trial participants ...
**MRO’s Bold Bet on AI Sparks New Race to Speed Up U.S. Clinical Trials**
NORRISTOWN, PA — The quest to accelerate clinical trials in the United States has taken a significant leap forward with MRO's acquisition of Clinetic, a cutting-edge recruitment management platform. This strategic move signals a growing emphasis on leveraging artificial intelligence (AI) to streamline the often lengthy and complex process of finding suitable participants for crucial medical research.
Clinetic, known for its rapid growth in the healthcare sector, utilizes AI to revolutionize how hospitals and life sciences companies identify, screen, and ultimately enroll individuals in clinical trials. Traditionally, this process can be a major bottleneck, delaying the development and approval of potentially life-saving treatments. The manual methods of sifting through patient data and contacting potential candidates are time-consuming and often inefficient.
By employing AI, Clinetic's platform can analyze vast amounts of data, including electronic health records, to pinpoint patients who meet the specific criteria for a given trial. This targeted approach not only speeds up the recruitment process but also improves the likelihood of finding qualified participants, leading to more robust and reliable trial results.
MRO's investment in Clinetic reflects a broader trend within the pharmaceutical and healthcare industries: the embrace of technology to overcome longstanding challenges. Clinical trials are essential for evaluating the safety and efficacy of new drugs and medical devices, and any improvement in their efficiency can have a profound impact on patient outcomes.
The acquisition is expected to create significant synergies, combining MRO's expertise in data management and release of information with Clinetic's innovative AI-powered recruitment capabilities. This collaboration promises to deliver a more comprehensive and streamlined solution for clinical trial sponsors and healthcare providers alike.
Industry analysts predict that this move will further fuel the race to adopt AI-driven solutions in clinical research. As competition intensifies, other companies are likely to explore similar strategies to enhance their recruitment processes and accelerate the development of new therapies. The ultimate beneficiaries of this technological advancement will undoubtedly be patients, who will gain access to innovative treatments faster than ever before.
NORRISTOWN, PA — The quest to accelerate clinical trials in the United States has taken a significant leap forward with MRO's acquisition of Clinetic, a cutting-edge recruitment management platform. This strategic move signals a growing emphasis on leveraging artificial intelligence (AI) to streamline the often lengthy and complex process of finding suitable participants for crucial medical research.
Clinetic, known for its rapid growth in the healthcare sector, utilizes AI to revolutionize how hospitals and life sciences companies identify, screen, and ultimately enroll individuals in clinical trials. Traditionally, this process can be a major bottleneck, delaying the development and approval of potentially life-saving treatments. The manual methods of sifting through patient data and contacting potential candidates are time-consuming and often inefficient.
By employing AI, Clinetic's platform can analyze vast amounts of data, including electronic health records, to pinpoint patients who meet the specific criteria for a given trial. This targeted approach not only speeds up the recruitment process but also improves the likelihood of finding qualified participants, leading to more robust and reliable trial results.
MRO's investment in Clinetic reflects a broader trend within the pharmaceutical and healthcare industries: the embrace of technology to overcome longstanding challenges. Clinical trials are essential for evaluating the safety and efficacy of new drugs and medical devices, and any improvement in their efficiency can have a profound impact on patient outcomes.
The acquisition is expected to create significant synergies, combining MRO's expertise in data management and release of information with Clinetic's innovative AI-powered recruitment capabilities. This collaboration promises to deliver a more comprehensive and streamlined solution for clinical trial sponsors and healthcare providers alike.
Industry analysts predict that this move will further fuel the race to adopt AI-driven solutions in clinical research. As competition intensifies, other companies are likely to explore similar strategies to enhance their recruitment processes and accelerate the development of new therapies. The ultimate beneficiaries of this technological advancement will undoubtedly be patients, who will gain access to innovative treatments faster than ever before.
Category:
World